Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of TMC647055 with Ritonavir and Simeprevir in Healthy Japanese Subjects
NCT02064842Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2014
- Primary completion
- Apr 2014
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TMC-647055 in hepatitis C (HCV) (10 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of participants with adverse events, Maximum observed plasma concentration at Day 10 and 2 more. Started Feb 2014; status: completed.
02
Drugs
TMC-647055
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02064842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02064842.